» Articles » PMID: 10720139

FLI-1 is a Suppressor of Erythroid Differentiation in Human Hematopoietic Cells

Overview
Journal Leukemia
Specialties Hematology
Oncology
Date 2000 Mar 17
PMID 10720139
Citations 50
Authors
Affiliations
Soon will be listed here.
Abstract

The FLI-1 oncogene, a member of the ETS family of transcription factors, is associated with both normal and abnormal hematopoietic cell growth and lineage-specific differentiation. We have previously shown that overexpression of FLI-1 in pluripotent human hematopoietic cells leads to the induction of a megakaryocytic phenotype. In this report we show that FLI-1 also acts as an inhibitor of erythroid differentiation. Following the induction of erythroid differentiation, pluripotent cells express reduced levels of FLI-1. In contrast, when FLI-1 is overexpressed in these cells, the levels of erythroid markers are reduced. The ability of FLI-1 overexpressing cells to respond to erythroid-specific inducers such as hemin and Ara-C is also inhibited, and the uninduced cells show a reduced level of the erythroid-associated GATA-1 transcription factor mRNA. Furthermore, expression of a GATA-1 promoter-driven reporter construct in K562 cells is inhibited by co-transfection with a construct expressing FLI-1. Our results support the hypothesis that FLI-1 can act both positively and negatively in the regulation of hematopoietic cell differentiation, and that inhibition of GATA-1 expression may contribute to FLI-1-mediated inhibition of erythroid differentiation.

Citing Articles

Acute Erythroid Leukemia: From Molecular Biology to Clinical Outcomes.

Fernandes P, Waldron N, Chatzilygeroudi T, Naji N, Karantanos T Int J Mol Sci. 2024; 25(11).

PMID: 38892446 PMC: 11172574. DOI: 10.3390/ijms25116256.


An intricate regulatory circuit between FLI1 and GATA1/GATA2/LDB1/ERG dictates erythroid vs. megakaryocytic differentiation.

Wang C, Hu M, Yu K, Liu W, Hu A, Kuang Y Mol Med Rep. 2024; 29(6).

PMID: 38695236 PMC: 11082641. DOI: 10.3892/mmr.2024.13231.


In vitro erythrocyte production using human-induced pluripotent stem cells: determining the best hematopoietic stem cell sources.

Cho Y, Kim H, Kwon S, Jeon S, Cheong J, Nam K Stem Cell Res Ther. 2023; 14(1):106.

PMID: 37101221 PMC: 10132444. DOI: 10.1186/s13287-023-03305-8.


ETV6 dependency in Ewing sarcoma by antagonism of EWS-FLI1-mediated enhancer activation.

Gao Y, He X, Wu X, Huang Y, Toneyan S, Ha T Nat Cell Biol. 2023; 25(2):298-308.

PMID: 36658219 PMC: 10101761. DOI: 10.1038/s41556-022-01060-1.


Current insights into the role of Fli-1 in hematopoiesis and malignant transformation.

Ben-David Y, Gajendran B, Sample K, Zacksenhaus E Cell Mol Life Sci. 2022; 79(3):163.

PMID: 35412146 PMC: 11072361. DOI: 10.1007/s00018-022-04160-1.